Brief: Jhbp Cy Says NMPA Approves Investigational NDA For Two Gb491 (Lerociclib) Bridging Studies
March 8 (Reuters) - JHBP CY Holdings Ltd 6998.HK :
* JHBP CY HOLDINGS LTD - NMPA ADMINISTRATION APPROVES
INVESTIGATIONAL NEW DRUG APPLICATION FOR TWO GB491 (LEROCICLIB)
BRIDGING STUDIES
Source text for Eikon: urn:newsml:reuters.com:*:nHKS8PWbSp
Further company coverage: 6998.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edding Genor group
See all newsBrief: JHBP CY Says Chairman And CEO Ni Xin To Buy Shares Up To USD 1 Million From Aug 31, 2026
Brief: Edding Genor Group Expects Revenue Of RMB850 MLN-RMB900 MLN For HY
Brief: Jhbp Cy Disposal Of Equity Interest In Candid Therapeutics
Edding Genor climbs on approval of clinical trial of cancer drug in China
Brief: JHBP CY's Phase Ib/Ii Clinical Trial Of Gb268 Obtains IND Approval By NMPA